2 citations
,
September 2020 in “Journal of Education Health and Sport” Higher IL-15 levels are linked to more severe hair loss in alopecia areata.
1 citations
,
September 2025 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.
1 citations
,
July 2025 in “Frontiers in Endocrinology” ApoBDs, once seen as waste, are now viewed as potential tools for disease treatment and tissue repair.
Including ineffective or unsafe doses in reviews can lead to misleading conclusions about alopecia areata treatments.
January 2026 in “Forum Dermatologicum” JAK inhibitors and combination therapies show promise for treating severe alopecia areata.
November 2025 in “Frontiers in Immunology” Immune cells are crucial for normal skin development and their dysfunction can cause skin disorders.
June 2025 in “International Journal of Science and Research (IJSR)” Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
December 2023 in “International journal of multidisciplinary research and analysis” SH-MSCs gel can effectively treat alopecia by increasing IL-10 and decreasing TNF-α gene expression.
September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
March 2017 in “Fundamental & Clinical Pharmacology” The model and estimator can predict drug exposure in kidney transplant patients well.
2 citations
,
August 2020 in “Journal of Cosmetic Dermatology” Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.
2 citations
,
October 2018 in “Archives of Dermatological Research” Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.
Baricitinib is more effective than methotrexate for severe alopecia areata.
3 citations
,
August 2025 in “Frontiers in Pharmacology” Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.
August 2025 in “Frontiers in Immunology” People with alopecia areata have a higher risk of heart disease.
7 citations
,
December 2020 in “Clinics in Dermatology” Some alopecia treatments might help treat COVID-19, but more research is needed.
148 citations
,
December 2018 in “Journal of autoimmunity” Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
83 citations
,
June 2018 in “Frontiers in immunology” Certain types of T cells are essential for healthy skin and play a role in skin diseases, but more research is needed to improve treatments.
74 citations
,
May 2016 in “Current opinion in pediatrics, with evaluated MEDLINE/Current opinion in pediatrics” Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.
59 citations
,
June 2022 in “Frontiers in medicine” There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.
39 citations
,
April 2016 in “Case Reports in Dermatology” Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
37 citations
,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
20 citations
,
January 2017 in “Actas Dermo-Sifiliográficas” Recent advances in hair loss treatments show significant progress.
May 2026 in “Frontiers in Cell and Developmental Biology” Collagen networks play a key role in hair loss and follicle miniaturization.
December 2025 in “Frontiers in Medicine” Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
January 2025 in “Universidad de Córdoba Insitutional Repository (Universidad de Córdoba)” An imbalanced scalp microbiome may worsen alopecia areata severity and inflammation, but treatment can partially restore balance.
October 2023 in “Frontiers in medicine” Targeted immunotherapy could be a promising new treatment for hair regrowth.